Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.

被引：1
|
作者：
Lopez, Juanita Suzanne
Plummer, Elizabeth Ruth
Devlin, Michael-John
Rulach, Robert
Garces, Alvaro Henrique Ingles
Haris, Noor R. Md
Miller, Rowan
Crawford, Donna
D'Arcangelo, Manolo
Aversa, Caterina
Hannah, Alison L.
Anderson, Stephanie
Engelhardt, Marc Frederick
Kaindl, Thomas
Larger, Patrice
Bachmann, Felix
Lane, Heidi A.
McKernan, Phil
Evans, T. R. Jeffry
Kristeleit, Rebecca Sophie
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Coll London Hosp, London, England
[5] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[6] UCL, Canc Inst, London, England
[7] Oncol Clin Trial Consulting, Sebastopol, CA USA
[8] Basilea Pharmaceut Int Ltd, Basel, Switzerland
[9] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2530
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors.
    Levy, Irit Carmi
    Amitzi, Leanne
    Lavi, Erez
    Zilony-Hanin, Neta
    Pode, Zohar
    Berger, Raanan
    Smith, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
    Kang, Yoon-Koo
    Ryu, Min -Hee
    Hong, Yong Sang
    Choi, Chang-Min
    Kim, Tae Won
    Ryoo, Baek-Yeol
    Kim, Jeong Eun
    Weis, John R.
    Kingsford, Rachel
    Park, Cheol Hee
    Jang, Seong
    Mcginn, Arlo
    Werner, Theresa L.
    Sharma, Sunil
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 743 - 750
  • [43] A phase I study of SB-408075 administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
    Helft, PR
    Schilsky, RL
    Kindler, HL
    Bertucci, D
    Dewitte, MH
    Martino, HK
    Friedman, CJ
    Erickson, JC
    Lambert, JM
    Ratain, J
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3786S - 3786S
  • [44] Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
    Shimizu, Toshio
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Kawakami, Hisato
    Watanabe, Satomi
    Yamamoto, Noboru
    Yonemori, Kan
    Koyama, Takafumi
    Sato, Jun
    Tamura, Kenji
    Kikuchi, Keiichi
    Akaike, Kenichiro
    Takeda, Shiho
    Takeda, Masayuki
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 1 - 12
  • [45] Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
    Toshio Shimizu
    Kazuhiko Nakagawa
    Hidetoshi Hayashi
    Tsutomu Iwasa
    Hisato Kawakami
    Satomi Watanabe
    Noboru Yamamoto
    Kan Yonemori
    Takafumi Koyama
    Jun Sato
    Kenji Tamura
    Keiichi Kikuchi
    Kenichiro Akaike
    Shiho Takeda
    Masayuki Takeda
    Investigational New Drugs, 2023, 41 : 1 - 12
  • [46] A phase I study of single-agent BEZ235 (SDS sachet), once-or twice-daily, in Japanese patients with advanced solid tumors.
    Watanabe, Koichiro
    Minami, Hironobu
    Otsu, Satoshi
    Hirashima, Yoshinori
    Morinaga, Ryotaro
    Nishikawa, Kazuo
    Hisamatsu, Yasushi
    Mukohara, Toru
    Kiyota, Naomi
    Chayahara, Naoko
    Toyoda, Masanori
    Imamura, Yoshinori
    Fujiwara, Yutaka
    Quadt, Cornelia
    Robson, Matthew
    Natsume, Kazuto
    Aoki, Takuji
    Shirao, Kuniaki
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [47] Phase 1 study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors.
    Rha, Sun Young
    Beom, Seung-Hoon
    Jung, Minkyu
    Shin, Young Geun
    Cheong, Jae-Ho
    Kim, Hyo Song
    Kim, Gun Min
    Chang, Jong Hee
    Lee, Young Woo
    Chong, Yunseon
    Yoo, Sanghee
    O'Neil, Vincent
    Janku, Filip
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] A Phase I study with fosfluridine tidoxil, a novel oral fluoropyrimidine, in patients with advanced solid tumors
    Vermorken, J. B.
    Schoeffski, P.
    Gruenwald, V.
    von Broen, I.
    Gruijs, S.
    de Boer, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 426 - 426
  • [49] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors.
    Filon, Olga
    Krivorotko, Petr
    Kobyakov, Grigory
    Razjivina, Viktoria
    Maximenko, Olga
    Gelperina, Svetlana
    Kreuter, Joerg
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345